S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:BMRN

BioMarin Pharmaceutical Stock Competitors

$86.00
-0.71 (-0.82%)
(As of 01/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$85.72
$87.85
50-Day Range
$80.74
$91.47
52-Week Range
$71.59
$92.17
Volume
985,834 shs
Average Volume
1.62 million shs
Market Capitalization
$15.79 billion
P/E Ratio
1,075.00
Dividend Yield
N/A
Beta
0.49

BioMarin Pharmaceutical (NASDAQ:BMRN) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, ALNY, INCY, EXAS, and RGEN

Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Exact Sciences (EXAS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

BioMarin Pharmaceutical vs.

Gilead Sciences (NASDAQ:GILD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends.

Gilead Sciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 94.2% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 1.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gilead Sciences currently has a consensus target price of $79.18, indicating a potential upside of 14.64%. BioMarin Pharmaceutical has a consensus target price of $112.57, indicating a potential upside of 30.90%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.57
BioMarin Pharmaceutical
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

Gilead Sciences has a net margin of 26.91% compared to BioMarin Pharmaceutical's net margin of 0.86%. Gilead Sciences' return on equity of 56.59% beat BioMarin Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences 26.91% 56.59% 16.36%
BioMarin Pharmaceutical 0.86% 2.02% 1.44%

Gilead Sciences received 922 more outperform votes than BioMarin Pharmaceutical when rated by MarketBeat users. Likewise, 79.18% of users gave Gilead Sciences an outperform vote while only 76.76% of users gave BioMarin Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2408
79.18%
Underperform Votes
633
20.82%
BioMarin PharmaceuticalOutperform Votes
1486
76.76%
Underperform Votes
450
23.24%

BioMarin Pharmaceutical has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$24.69 billion3.51$123 million$5.8611.79
BioMarin Pharmaceutical$1.86 billion8.49$859.10 million$0.081,075.00

In the previous week, Gilead Sciences had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Gilead Sciences and 12 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.12 beat Gilead Sciences' score of 0.00 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Neutral
BioMarin Pharmaceutical
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BioMarin Pharmaceutical beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BioMarin Pharmaceutical (NASDAQ:BMRN) vs. Its Competitors

TypeBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.79B$5.77B$4.69B$7.20B
Dividend YieldN/A2.49%2.01%2.87%
P/E Ratio1,075.0013.7517.2718.91
Price / Sales8.49494.786,141.08232.73
Price / Cash71.7621.3134.0337.33
Price / Book3.808.857.789.28
Net Income$859.10M$98.81M$98.51M$156.13M
7 Day Performance-2.45%-3.30%-2.53%-3.29%
1 Month Performance-1.02%-12.53%-7.64%-5.15%
1 Year Performance-2.26%-30.12%-20.24%-8.71%

BioMarin Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
2.6991 of 5 stars
$231.30
-1.1%
$232.24
-0.4%
-6.8%$130.28B$25.42B23.8224,300
GILD
Gilead Sciences
3.3238 of 5 stars
$69.07
-2.0%
$79.18
-14.6%
+3.0%$86.64B$24.69B11.7913,600Analyst Report
REGN
Regeneron Pharmaceuticals
2.6092 of 5 stars
$618.11
-1.1%
$731.41
-18.3%
+15.8%$66.47B$8.50B9.879,123Analyst Report
VRTX
Vertex Pharmaceuticals
1.95 of 5 stars
$230.84
-0.1%
$251.24
-8.8%
-0.5%$58.69B$6.21B27.713,400
BIIB
Biogen
2.1681 of 5 stars
$230.81
-1.3%
$309.06
-33.9%
-15.7%$33.90B$13.44B22.589,100Analyst Report
SGEN
Seagen
2.692 of 5 stars
$132.55
-1.7%
$183.09
-38.1%
-29.8%$24.24B$2.18B-71.652,092Analyst Report
Insider Selling
News Coverage
ALNY
Alnylam Pharmaceuticals
2.5 of 5 stars
$138.62
-0.4%
$208.38
-50.3%
-17.7%$16.58B$492.85M-19.441,453Analyst Report
INCY
Incyte
2.9083 of 5 stars
$74.78
-0.3%
$89.73
-20.0%
-20.4%$16.52B$2.67B31.031,773Analyst Upgrade
Short Interest ↓
EXAS
Exact Sciences
2.3909 of 5 stars
$76.13
-1.7%
$136.09
-78.8%
-48.8%$13.12B$1.49B-15.324,900
RGEN
Repligen
2.3831 of 5 stars
$189.58
-1.6%
$316.86
-67.1%
-14.7%$10.48B$366.26M90.281,128
UTHR
United Therapeutics
2.1415 of 5 stars
$205.07
-3.4%
$224.38
-9.4%
+19.5%$9.24B$1.48B20.78950Short Interest ↓
Positive News
NVAX
Novavax
2.125 of 5 stars
$92.33
-6.6%
$265.00
-187.0%
-27.9%$6.98B$475.60M-6.23791
NBIX
Neurocrine Biosciences
2.8529 of 5 stars
$72.83
-2.3%
$117.57
-61.4%
-33.0%$6.91B$1.05B15.94845Analyst Downgrade
ARNA
Arena Pharmaceuticals
1.7631 of 5 stars
$91.51
-0.5%
$96.67
-5.6%
+13.4%$5.63B$320K-9.44363
EXEL
Exelixis
2.7481 of 5 stars
$17.08
-1.8%
$33.10
-93.8%
-27.6%$5.40B$987.54M33.49773News Coverage
HALO
Halozyme Therapeutics
2.6188 of 5 stars
$33.75
-1.1%
$55.33
-64.0%
-30.1%$4.75B$267.59M12.10136
IONS
Ionis Pharmaceuticals
1.7931 of 5 stars
$30.32
-0.7%
$48.06
-58.5%
-50.3%$4.28B$729M-7.17757
ALKS
Alkermes
2.1431 of 5 stars
$25.00
-0.9%
$28.71
-14.9%
+9.4%$4.04B$1.04B-43.102,245
OPK
OPKO Health
1.9398 of 5 stars
$4.43
-6.5%
$6.33
-43.0%
-2.4%$3.02B$1.44B40.285,269Analyst Report
FOLD
Amicus Therapeutics
2.1148 of 5 stars
$9.54
-0.9%
$15.50
-62.5%
-56.3%$2.66B$260.89M-10.60483Analyst Revision
BCRX
BioCryst Pharmaceuticals
2.2042 of 5 stars
$14.54
-0.2%
$19.82
-36.3%
+60.4%$2.60B$17.81M-11.45246
EBS
Emergent BioSolutions
2.6664 of 5 stars
$45.59
-3.6%
$92.25
-102.3%
-57.3%$2.45B$1.56B10.852,200Short Interest ↑
MYGN
Myriad Genetics
1.5448 of 5 stars
$26.68
-1.1%
$30.00
-12.4%
-2.1%$2.13B$638.60M-30.672,700
CCXI
ChemoCentryx
2.1331 of 5 stars
$29.49
-4.1%
$75.00
-154.3%
-51.6%$2.06B$64.89M-16.95133News Coverage
Gap Up
LGND
Ligand Pharmaceuticals
2.1598 of 5 stars
$115.97
-0.7%
$223.75
-92.9%
-11.3%$1.94B$186.42M29.072,018
IRWD
Ironwood Pharmaceuticals
2.2831 of 5 stars
$11.19
-2.2%
$14.50
-29.6%
+1.9%$1.83B$389.52M3.44232
DVAX
Dynavax Technologies
2.5881 of 5 stars
$12.73
-0.0%
$23.50
-84.6%
+149.6%$1.53B$46.55M-36.37245News Coverage
CLDX
Celldex Therapeutics
2.2 of 5 stars
$30.32
-2.4%
$59.00
-94.6%
+69.0%$1.41B$7.42M-17.23124
CDXS
Codexis
2.0798 of 5 stars
$21.49
-2.5%
$32.80
-52.6%
-18.6%$1.39B$69.06M-89.54181
IMGN
ImmunoGen
1.8931 of 5 stars
$5.84
-1.4%
$9.50
-62.7%
-26.4%$1.18B$132.30M-17.1879Short Interest ↑
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$68.34
-5.4%
$177.57
-159.8%
-37.7%$1.17BN/A-4.6642
INVA
Innoviva
1.7165 of 5 stars
$16.44
-0.1%
N/A+29.1%$1.14B$336.79M5.275
MNKD
MannKind
1.6498 of 5 stars
$4.02
-1.2%
$6.30
-56.7%
+25.2%$1.01B$65.14M-12.56241
SGMO
Sangamo Therapeutics
1.8731 of 5 stars
$6.02
-1.5%
$18.40
-205.6%
-61.3%$876.96M$118.19M-4.74413
VNDA
Vanda Pharmaceuticals
2.4814 of 5 stars
$13.90
-2.0%
$20.00
-43.9%
-0.4%$774.40M$248.17M22.79292
AGEN
Agenus
2.1598 of 5 stars
$2.81
-1.1%
$11.50
-309.3%
-19.9%$721.70M$88.17M-23.42359Short Interest ↑
Gap Up
ICPT
Intercept Pharmaceuticals
2.2583 of 5 stars
$17.45
-5.1%
$30.21
-73.1%
-37.9%$515.60M$312.69M-5.39498Gap Up
LXRX
Lexicon Pharmaceuticals
1.9714 of 5 stars
$3.31
-0.6%
$11.67
-252.5%
-58.3%$492.85M$24M-6.9078
RIGL
Rigel Pharmaceuticals
1.9931 of 5 stars
$2.28
-2.6%
$9.50
-316.7%
-39.5%$389.89M$108.62M-25.33169
GERN
Geron
1.7998 of 5 stars
$1.10
-0.0%
$5.50
-400.0%
-37.9%$354.14M$250K-3.3354Analyst Downgrade
CLVS
Clovis Oncology
2.0148 of 5 stars
$2.44
-0.0%
$6.88
-181.8%
-60.1%$317.15M$164.52M-0.86N/AGap Up
CRIS
Curis
1.9398 of 5 stars
$3.33
-3.6%
$19.80
-494.6%
-73.0%$305.06M$10.84M-7.2428
VSTM
Verastem
2.2314 of 5 stars
$1.59
-3.8%
$6.33
-298.3%
-35.1%$289.68M$88.52M-3.6149
SABS
SAB Biotherapeutics
2.0333 of 5 stars
$5.74
-2.3%
$20.33
-254.2%
N/A$249.55MN/A0.005
XOMA
XOMA
1.7131 of 5 stars
$20.77
-0.6%
$49.00
-135.9%
-49.3%$234.93M$29.39M-103.8510Short Interest ↑
FBIO
Fortress Biotech
2.0914 of 5 stars
$2.10
-2.9%
$12.80
-509.5%
-41.7%$209.22M$45.60M-4.47111Short Interest ↑
ZIOP
ZIOPHARM Oncology
2.1031 of 5 stars
$0.90
-4.5%
$3.50
-290.6%
-75.8%$193.67MN/A-2.08105Analyst Downgrade
MTEM
Molecular Templates
2.5814 of 5 stars
$3.34
-3.0%
$13.20
-295.2%
-71.7%$188.06M$18.84M-1.76239
SPPI
Spectrum Pharmaceuticals
2.2848 of 5 stars
$1.07
-1.9%
$5.00
-367.3%
-73.1%$175.43MN/A-1.00176
BOLT
Bolt Biotherapeutics
2.3064 of 5 stars
$4.00
-9.8%
$39.80
-895.0%
N/A$149.14M$230K-0.2465
This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.